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Abstract
Background: The aim of this study was to investigate the prevalence and prognostic significance of psychological
distress in gastric cancer patients.
Methods: The study population included 229 gastric cancer patients visiting Yonsei Cancer Center between
November 2009 and March 2011. The distress was measured by available tools including the Modified Distress
Thermometer (MDT), Hospital Anxiety and Depression Scale (HADS), and Center for Epidemiologic Studies–Depression
Scale (CES-D). Patients with psychological distress were defined as those who scored above the cut-off values in both
the MDT and either one of the HADS or CES-D.
Results: The median age of patients was 56 (range, 20 to 86) and 97 (42.4%) patients were with stage IV disease status
at enrollment. The overall prevalence of psychological distress was 33.6% (95% CI: 27.5–39.8%) in 229 gastric cancer
patients. In multiple logistic regression analysis, lower education level (odds ratio [OR] 2.39; 95% confidence interval [CI]
1.11–5.17, P = 0.026) and higher disease stage (OR 2.72; 95% CI 1.47–5.03, P = 0.001) were associated with
psychological distress. In stage I-III disease, patients with psychological distress had worse disease-free survival (DFS)
(5-year DFS rate: 60% vs 76%, P = 0.49) compared with those without psychological distress. In stage IV disease
(n = 97), patients with psychological distress showed poorer overall survival than those without psychological distress
(median OS (Overall Survival): 12.2 vs. 13.8 months, P = 0.019).
Conclusion: Psychological distress is common in patients with all stages of gastric cancer and is associated with worse
outcomes.
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Background
Cancer diagnosis and treatment is a significantly stress-
ful event that generates psychological distress in a large
number of cancer patients. Psychological distress is gen-
erally defined as a state of emotional suffering character-
ized by symptoms of depression and anxiety [1].
Approximately 20–40% of cancer patients show a signifi-
cant level of psychological distress [2, 3]. Distress can
exert a negative impact on their treatment adherence,
quality of life (QOL), pain, and even on survival [4–8].
Recently, in most solid cancers including gastric cancer,
the multidisciplinary approach is becoming more
important for the decision of cancer treatment strategy
and psychosocial support is one of the essential parts of
the multidisciplinary approach [9, 10].
Gastric cancer is the second leading cause of cancer
deaths in the world [11]. Most patients with gastric cancer
have advanced to an incurable stage at the time of diagno-
sis, which induces tremendous psychological stress. Even if
the patient is diagnosed with early-stage gastric cancer, they
suffer from not only the diagnosis of cancer but also sur-
gery itself [12]. Therefore, the importance of psychological
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distress in gastric cancer patients for the decision of treat-
ment will continue to grow.
Few studies have reported on the prevalence or the na-
ture of psychological distress in gastric cancer patients.
Tavoli et al. reported that overall 47.2% and 57% of
patients with gastrointestinal cancer scored high on both
anxiety and depression respectively [13]. We previously
reported the prevalence and associated factors of psycho-
logical distress in all types of cancer patients and found
that 28.3% of gastric cancer patients had psychological
distress [14]. Further, there is no report of the survival im-
pact of psychological distress in gastric cancer patients.
The aim of this study was to evaluate the prevalence
and prognostic impact of psychological distress in gastric
cancer patients.
Methods
Study population
Patients were eligible for study participation if they met
the following criteria: 1) histologically confirmed gastric
adenocarcinoma; 2) age of >20 years; 3) Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus 0–3; 4) the ability to read and understand the ques-
tionnaire; 5) the ability to communicate in written and
spoken language; and 6) willing and able to provide
written informed consent.
Patients with operable gastric cancer underwent surgery
and then received adjuvant chemotherapy according to
the final pathologic stage. Stage IV gastric cancer patients
received a standard treatment of palliative systemic
chemotherapy with or without palliative gastrectomy.
Patients with gastric cancer visiting Yonsei Cancer
Center, Severance Hospital in Seoul, Korea between
November 2009 and March 2011 were included. Patients
were enrolled at the first visit to the medical oncology
department. During the study period, 298 gastric cancer
patients agreed to complete questionnaires for screening
distress. Among them, 249 (83.5%) patients completed all
questionnaires. We excluded 20 patients in the final ana-
lysis due to several reasons (such as neoadjuvant chemo-
therapy, follow-up loss, treatment refusal, etc.) Finally, we
analyzed the data of 229 gastric cancer patients (Fig. 1).
Study procedure
An Oncology Certified Nurse (OCN) explained the
purpose and procedure of the distress screening pro-
gram to gastric cancer patients in the oncology out-
patient clinic. Patients who signed informed consent
forms completed questionnaires containing the Modified
Distress Thermometer (MDT), Hospital Anxiety and
Depression Scale (HADS), and Center for Epidemiologic
Studies-Depression Scale (CES-D), and questions about
socio-demographic and clinical status. Cancer-related in-
formation including cancer stage, disease-free survival,
overall survival, and adjuvant chemotherapy were col-
lected in electronic medical records. The patients who
were identified as harboring psychological distress were
referred to a psychiatrist for further evaluation and treat-
ment for psychological distress by a medical oncologist.
An independent psychiatric doctor reviewed the data
without any clinical information and informed the
oncologist about the status of psychological distress.
Measure of psychological distress
The following three self-administered questionnaires
were used to evaluate the psychological distress of
enrolled patients.
The MDT is an easily used screening tool to measure
the severity of psychological symptoms including anx-
iety, insomnia, and depression, and the degree of func-
tional impairment due to these symptoms. It contains
three subscales: MDT-anxiety, MDT-insomnia, and
MDT-depression. Patients are required to circle the
number that corresponds to their severity of distress and
the degree of functional impairment on an 11-point
visual analogue scale ranging from 0 to 10 by referring to
the previous week. More than 4 points in both the severity
and impairment scales in each distress symptom indicates
that it is necessary to refer to a psychiatrist [15].
The HADS is widely used to measure anxiety and de-
pression in patients with medical illness. It is considered
as an effective screening tool to evaluate psychological
distress in cancer patients [16, 17]. It consists of two
subscales (HADS-A and HADS-D) that evaluate anxiety
and depression, respectively. We used the Korean-
validated version of the HADS for this study. Scores for
each subscale range from 0 to 21 and a cut-off score of 8
was used, which had been previously reported to show
good sensitivity and specificity (89.2 and 82.5%, respect-
ively) in a Korean population [18]. Patients who scored
Fig. 1 Study Population
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above the cut-off score in either the HADS-A or HADS-
D scale were defined as one with psychological distress
based on the HADS.
The CES-D is a 20-item tool used to evaluate depres-
sive symptoms in the general population. The Korean
version of the CES-D was used in this study and we de-
fined a CES-D score of 21 as the cut-off score, which
was reported to be the threshold for the purpose of esti-
mating the prevalence of depressive symptoms in
Korean patients [19].
In this study, patients with psychological distress were
defined as those who scored above the cut-off value in
both MDT scales and either one of the HADS or CES-D
scales.
Statistical analysis
In order to compare psychological distress with regard
to socio-demographic and clinical characteristics, chi-
square tests were conducted for categorical and nominal
variables, and independent samples t-test and analyses of
variance (ANOVA) were performed for continuous vari-
ables. Standard univariate descriptive statistics were used
to calculate the prevalence of distress. Logistic regres-
sion analysis was conducted to evaluate the factors that
show the strongest association with psychological dis-
tress. Univariate and multivariate Cox proportional haz-
ards models were used to determine the effect of
independent predictors on survival times. Disease-free
survival (DFS) was defined as the time from the date of
surgery to the disease recurrence or death from any
other causes. All statistical analysis was conducted using
SPSS, software version 23.0 (SPSS Inc.).
Results
Patient characteristics
Table 1 shows the socio-demographic and clinical data
of the evaluable 229 patients. The median age of the pa-
tients was 56 years (range: 20–86), and 167/229 (73%)
were male. Most patients were married (196/229
[85.6%]), and more than half of the participants were
high school educated or higher (178/229 [77.8%]) and
unemployed (121/229 [52.8%]). Patients with metastatic
or recurrent disease (stage IV) at enrollment were
42.4%. Most of the patients were non-smokers (79.9%)
and physically active (ECOG 0 or 1: 94.7%). Among
stage I-III disease patients (n = 132), 83 patients received
adjuvant chemotherapy after surgery. The proportion of
patients who received adjuvant chemotherapy in stage I,
II, and III was 2.9%, 81.8%, and 83.1%, respectively. The
most commonly used chemotherapy regimen was
platinum-based doublet, for 67.5% with an adjuvant aim
and 73.1% with a palliative aim. Of 97 patients with re-
current or metastatic disease at enrollment, more than
half of the patients (53.6%) had peritoneal metastases at
Table 1 Baseline characteristics
N = 229 %
Age
Median 56
Range 20–86
Gender
Male 167 72.9
Female 62 27.1
ECOG Performance
0 121 52.8
1 96 41.9
2–3 12 5.2
Smoking
Smoker 46 20.1
Non-Smoker 183 79.9
Marital status
Married 196 85.6
Single 17 7.4
Widowed 12 5.2
Divorced 4 1.7
Educational level
Elementary school 24 10.5
Middle school 27 11.8
High school 86 37.6
Undergraduate 74 32.3
Graduate school 18 7.9
Employment status
Full-time job 82 35.8
Part-time job 26 11.4
Unemployed 82 35.8
Housewife/Student 39 17
Histology
Tubular adenocarcinoma 161 70.3
Signet ring cell carcinoma 58 25.3
Mucinous carcinoma 5 2.2
Others 5 2.2
Adjuvant chemotherapy
Platinum-based doublet (SP or FP) 56/83 67.5
TS-1 monotherapy 22/83 26.5
Others 5/83 6
Initial metastasis site
Peritoneum 52/97 53.6
Distant LN 41/97 42.3
Liver 28/97 28.9
Bone 12/97 12.4
Lung 9/97 9.3
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diagnosis and 84.5% received palliative chemotherapy in
the first-line setting. Fifteen patients with recurrent or
metastatic disease underwent palliative surgery for
several purposes such as clinical trials (n = 4), good
responder to palliative chemotherapy (n = 8), and palli-
ation of symptoms (n = 3).
Prevalence of psychological distress in gastric cancer
patients
The results of distress screening through the question-
naires are shown in Table 2. Among the 229 patients, 77
(33.6%) were identified as patients with psychological
distress. Using the MDT, 50 patients reported insomnia
(21.8%), 69 anxiety (30.1%), or 68 depression (29.7%).
The number of patients who scored above the cutoff
value in HADS-A, HADS-D, and CES-D was 62 (27.1%),
92 (40.2%), and 76 (33.2%), respectively. Concordance
between the parameters are displayed in Fig. 2. Among
77 patients with psychological distress, 61% had positive
results for all three methods. Patients who are in the
shaded area in Fig. 2c were defined as patients with
psychological distress. The prevalence of psychiatric
illness diagnosed by the psychiatrist is shown in
Additional file 1: Table S1.
Risk factors of psychological distress
Table 3 describes the comparison of socio-demographic
and clinical factors between patients with and without
psychological distress. Patients with psychological dis-
tress were significantly higher in females (P = 0.024), the
unemployed (P = 0.02), those with lower educational
background (P = 0.021), and those at an advanced stage
(P = 0.008). The logistic regression analysis showed that
education, disease stage, and smoking status maintained
a statistically significant association with psychological
distress (Additional file 1: Table S2). The patients with
low education levels were 2.39 times (95% CI, 1.11–5.17,
P = 0.026) more likely to have psychological distress
than those with high education levels. The patients with
stage IV incurable disease stage were 2.72 times (95%
CI, 1.47–5.03, P = 0.001) more likely to have psycho-
logical distress than those with a curable disease stage.
Survival analysis
The median follow-up duration of the entire cohort was
42.5 months. We analyzed survival data divided into two
subsets (curable disease, stage I-III vs. incurable disease,
stage IV). DFS by TNM (Tumor/Node/Metastasis) sub-
stage are shown in Additional file 1: Figure S1. In stage
I-III disease, patients who have psychological distress
had worse disease-free survival (5-year DFS rate: 60% vs
76%, P = 0.49, Fig. 3a). In stage IV disease, patients with
psychological distress had worse OS than those without
psychological distress (median OS: 12.2 vs. 13.8 months,
P = 0.019, Fig. 3b).
Table 1 Baseline characteristics (Continued)
Brain 2/97 2.1
Others 19/97 19.6
Palliative chemotherapy
No 15/97 15.5
Yes 82/97 84.5
Palliative chemotherapy regimen
Platinum-based doublet (SP or FP) 60/82 73.2
Taxane-based regimen 12/82 14.6
Triplet (DCF) 2/82 2.4
Others 8/82 9.7
AJCC stage at enrollment
1 34 14.8
2 33 14.4
3 65 28.4
4 97 42.4
Table 2 Prevalence of psychological distress by disease stage
All Patients Stage I-III Stage IV
N = 229 % N = 132 % N = 97 % P-value
MDT 93 40.6 46 34.8 47 48.5 0.038
Insomnia 50 21.8 28 21.2 22 22.7 0.79
Anxiety 69 30.1 30 22.7 39 40.2 0.004
Depression 68 29.7 31 23.5 37 38.1 0.016
HADS 106 46.3 52 39.4 54 55.7 0.015
HADS-A 62 27.1 29 22 33 34 0.043
HADS-D 92 40.2 45 34.1 47 48.5 0.028
CES-D 76 33.2 38 28.8 38 39.2 0.099
Psychological distress 77 33.6 35 26.5 42 43.3 0.008
MDT Modified Distress Thermometer, HADS Hospital Anxiety and Depression Scale, CES-D Center for Epidemiologic Studies-Depression Scale
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The Cox multivariate analysis model including age,
gender, ECOG, adjuvant chemotherapy, marriage, educa-
tion, employment, and psychological distress in stage III
disease showed that adjuvant chemotherapy (Hazzard
ratio [HR] 7.23, 95% CI 2.27–22.95, P < 0.001) and psy-
chological distress (HR 2.47, 95% CI 1.07–5.68,
P = 0.034) were associated with shorter disease free
survival (Table 4).
Discussion
Psychological support is an important part of the multi-
disciplinary approach, but there is no study that specific-
ally evaluated the psychological distress in gastric cancer,
which is the most common cancer in Korea. To our
knowledge, this is the first study to explore the preva-
lence and prognostic impact of psychological distress
among a large number of patients with gastric cancer. In
our study cohort of gastric cancer patients, significant
psychological distress was identified in 33.6% of patients.
In addition, we found that psychological distress has a
poor prognostic impact for gastric cancer patients.
The presence of psychological distress is a risk factor
for treatment noncompliance. A meta-analysis showed
that noncompliance was greater in patients with depres-
sion compared to non-depressed patients [20]. There-
fore, it is important to identify the patients who may be
vulnerable to psychological distress to improve treat-
ment adherence. We found that the patients with
advanced disease, low levels of education, and who were
female were found to be significantly vulnerable to
psychological distress. These findings are comparable to
previous studies [21–24]. Several studies reported a
higher prevalence of psychological distress in patients
with lower education. Lower coping skills seem to
contribute to the higher rate of psychological distress in
those with little education [24].
Kuchler et al. reported that patients with gastrointestinal
cancer including stomach, pancreatic, liver, or colorectal
cancer who received a formal program of psychothera-
peutic support during their hospital stay showed a better
survival than those who did not [25]. In this study popula-
tion, there were few recurrence cases in stage I or II dis-
ease; therefore, we performed a multivariate survival
analysis in stage III disease. Although not statistically
significant, patients who had psychological distress were
less likely to receive adjuvant chemotherapy than those
who did not. Treatment non-compliance related with
adjuvant therapy could be one of the reasons for the poor
survival in patients with psychological distress.
There are many screening tools with variable formats
and lengths for evaluating psychological distress. How-
ever, it is not clear which screening method is appropri-
ate for cancer patients. The Distress Thermometer (DT)
is widely used due to its simplicity, but it is generally
poor accuracy was pointed as a limitation [26]. To com-
pensate this weakness, we added two other scales for the
evaluation of psychological distress. In this study, we
also have to consider the balance between minimizing
the burden on patients and maximizing validity of data.
We selected three short-length screening tools—MDT,
HADS, and CES-D—that were validated by several stud-
ies [27]. We also previously reported the sensitivity and
Fig. 2 Concordance rate between distress measure parameters (a) MDT (b) HADS (c). All three distress parameters; Shaded area are the patient
who was defined as psychological distress in this study
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Table 3 Comparison of socio-demographic characteristics between the patients with psychological distress and those without
psychological distress
Patients without psychological distress Patients with psychological distress
N = 152 % N = 77 % P-value
Age 0.289
Mean (SD) 57 (13) 55 (12.7)
Gender 0.024
Male 118 77.6 49 63.6
Female 34 22.4 28 36.4
ECOG Performance 0.055
0 82 53.9 39 50.6
1 66 43.4 30 39
2–3 4 2.6 8 10.4
Smoking 0.056
Smoker 116 76.3 67 87
Non-Smoker 36 23.7 10 13
Marital status 0.247
Married 133 87.5 63 81.8
Unmarried 19 12.5 14 18.2
Educational status 0.021
≤ Middle school 27 17.8 24 31.2
≥ High school 125 82.2 53 68.8
Employment status 0.02
Employed 80 52.6 28 36.4
Unemployed 72 47.4 9 63.6
Disease stage at enrollment 0.008
1–3 97 63.8 35 45.5
4 55 36.2 42 54.5
Disease status at enrollment 0.072
Post-op status 64 42.1 23 29.9
Pre-op or metastatic 88 57.9 54 70.1
SD Standard Deviation, ECOG Eastern Cooperative Oncology Group
Fig. 3 (a) DFS in Stage I-III disease and (b) OS in Stage IV disease by psychological distress
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specificity of these tools in Korean cancer patients [14].
However, considering that 49 (16.5%) patients did not an-
swer the questions completely, filling out all three ques-
tionnaires was clearly some burden to cancer patients.
Further studies are warranted to develop efficient tools
reflecting the distinct characteristics of Korean culture.
There are several limitations in our study. First, the
timing of surveillance was not consistent in all popula-
tions. Some patients filled out the questionnaires after
hearing the prognosis of their disease, and others did
when not knowing their prognosis or treatment plan.
Second, we could not follow the development of psycho-
logical distress over the trajectory of cancer because of
our cross-sectional design. Third, these data were ob-
tained by self-report, and it is possible that patients may
have under- or overestimated their status. Fourth, sys-
temic chemotherapy for metastatic gastric cancer was
not standardized.
Despite these limitations, this study has important
strengths. First, our study demonstrates that approximately
one-third of gastric cancer patients have significant psycho-
logical distress, especially in low-educated patients with ad-
vanced stage disease. The patients with psychological
distress showed poor survival outcomes that may be related
with treatment non-compliance.
Conclusions
Psychological distress is common in patients with all
stages of gastric cancer and is associated with worse out-
comes. From these results, we conclude that we need to
pay attention to the psychological status of gastric cancer
patients. Ultimately, further research is needed to investi-
gate whether psychotherapeutic interventions would de-
crease the distress and improve survival outcomes in
gastric cancer patients.
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